IgM-Enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis: A Before-After Cohort Study

2016 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​IgM-Enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis: A Before-After Cohort Study​
Wand, S.; Klages, M.; Kirbach, C.; Warszawska, J.; Meybohm, P.; Zacharowski, K. & Koch, A.​ (2016) 
PLoS ONE11(8) art. e0160907​.​ DOI: https://doi.org/10.1371/journal.pone.0160907 

Documents & Media

journal.pone.0160907.pdf360.06 kBAdobe PDF

License

Published Version

Attribution 4.0 CC BY 4.0

Details

Authors
Wand, Saskia; Klages, Matthias; Kirbach, Christin; Warszawska, Joanna; Meybohm, Patrick; Zacharowski, Kai; Koch, Alexander
Abstract
Introduction Sepsis remains associated with a high mortality rate. Endotoxin has been shown to influence viscoelastic coagulation parameters, thus suggesting a link between endotoxin levels and the altered coagulation phenotype in septic patients. This study evaluated the effects of systemic polyspecific IgM-enriched immunoglobulin (IgM-IVIg) (Pentaglobin (R) [Biotest, Dreieich, Germany]) on endotoxin activity (EA), inflammatory markers, viscoelastic and conventional coagulation parameters. Methods Patients with severe sepsis were identified by daily screening in a tertiary, academic, surgical ICU. After the inclusion of 15 patients, the application of IgM-IVIg (5 mg/kg/d over three days) was integrated into the unit's standard operation procedure (SOP) to treat patients with severe sepsis, thereby generating "control" and "IgM-IVIg" groups. EA assays, thrombelastometry (ROTEM (R)) and impedance aggregometry (Multiplate (R)) were performed on whole blood. Furthermore, routine laboratory parameters were determined according to unit's standards. Results Data from 26 patients were included. On day 1, EA was significantly decreased in the IgM-IVIg group following 6 and 12 hours of treatment (0.51 +/- 0.06 vs. 0.26 +/- 0.07, p < 0.05 and 0.51 +/- 0.06 vs. 0.25 +/- 0.04, p < 0.05) and differed significantly compared with the control group following 6 hours of treatment (0.26 +/- 0.07 vs. 0.43 +/- 0.07, p < 0.05). The platelet count was significantly higher in the IgM-IVIg group following four days of IgM-IVIg treatment (200/nl +/- 43 vs. 87/nl +/- 20, p < 0.05). The fibrinogen concentration was significantly lower in the control group on day 2 (311 mg/dl +/- 37 vs. 475 mg/dl +/- 47 (p = 0.015)) and day 4 (307 mg/dl +/- 35 vs. 420 mg/dl +/- 16 (p = 0.017)). No differences in thrombelastometric or aggregometric measurements, or inflammatory markers (interleukin-6 (IL-6), leukocyte, lipopolysaccharide binding protein (LBP)) were observed. Conclusion Treatment with IgM-enriched immunoglobulin attenuates the EA levels in patients with severe sepsis and might have an effect on septic thrombocytopenia and fibrinogen depletion. Viscoelastic, aggregometric or inflammatory parameters were not influenced.
Issue Date
2016
Status
published
Publisher
Public Library Science
Journal
PLoS ONE 
ISSN
1932-6203
Sponsor
Open-Access-Publikationsfonds 2016

Reference

Citations


Social Media